Long-term statin use linked to lower dementia risk, study finds
A 15-year study tracking over 132,000 people in Denmark found that statin users had a 10% lower risk of developing dementia, with early use reducing risk by 15%. The findings, presented at the European Society of Cardiology congress, suggest that cholesterol-lowering drugs may protect brain health. Researchers believe statins help by reducing LDL cholesterol, which can impair blood flow to the brain.
The 15-year Danish study followed 132,585 people with type 2 diabetes, comparing those who began statins during the tracking period against non-users. Early statin initiation was linked to a 15% lower dementia risk, while any use during the study showed a 10% reduction, with similar effects across sexes. Researchers presented the findings at the European Society of Cardiology congress and published them in the Lancet Regional Health Europe. The proposed mechanism centers on LDL cholesterol: by lowering it, statins may prevent plaque-driven narrowing of brain blood vessels, a pathway implicated in dementia. The study adds to a broader Lancet commission estimate that addressing 14 modifiable risk factors—including high LDL from midlife—could prevent or delay 45% of dementia cases.
This study could influence public health guidance, particularly for middle-aged adults with diabetes or elevated cholesterol, who may see statins as a dual-purpose preventive measure. If confirmed, the modest risk reduction—10–15%—might encourage earlier screening and treatment, potentially easing future dementia burdens as global cases approach 153 million by 2050. However, statins are already widely prescribed, so the practical impact may hinge on timing and patient adherence rather than new prescriptions. The findings could also prompt further research into cholesterol’s role in brain health, though causality remains uncertain.